Study on the Effectiveness and Safety of Linggui Qihua No.2 Prescription in Treating Heart Failure with Preserved Ejection Fraction
10.19879/j.cnki.1005-5304.202410581
- VernacularTitle:苓桂气化2号方治疗射血分数保留的心力衰竭有效性及安全性研究
- Author:
Siyu LIU
1
;
Wenbo QIAO
;
Xiaoyu LIANG
;
Yujiao SHI
;
Yongcheng LIU
;
Chenguang YANG
;
Guoju DONG
Author Information
1. 中国中医科学院西苑医院,北京 100091;中国中医科学院研究生院,北京 100700
- Publication Type:Journal Article
- Keywords:
heart failure with preserved ejection fraction;
Linggui Qihua No.2 Prescription;
randomized controlled trial;
efficacy;
safety
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2025;32(6):167-172
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of Linggui Qihua No.2 Prescription(LGQH2)in patients with heart failure with preserved ejection fraction(HFpEF).Methods Totally 60 HFpEF patients were randomly divided into experimental group and control group according to random number table method,with 30 patients in each group.On the basis of standardized treatment for heart failure,the experimental group was given LGQH2 granules,13 g/time,twice a day,orally;the control group was given placebo granules of LGQH2,with the same administration method as the experimental group.The treatment course for both groups was 4 weeks.6-minute walking distance(6MWD),Kansas City Cardiomyopathy Questionnaire(KCCQ)score,TCM syndrome score and serum NT-proBNP levels.Echocardiography was used to detect the ratio of early diastolic blood flow velocity(E)at the mitral valve to early diastolic myocardial motion velocity(e')at the mitral annulus,left atrial diameter(LAD),left ventricular end-diastolic diameter(LVEDD)and interventricular septal thickness(IVST).Adverse reactions and events were also recorded.Results Compared with before treatment,both groups showed significant improvement in 6MWD,KCCQ score,TCM syndrome score,serum NT proBNP,and E/e'after treatment(P<0.05),and there was no statistical significance in LAD,LVEDD and IVST between the two groups(P>0.05);after treatment,the experimental group showed better improvement in 6MWD,KCCQ score,TCM syndrome score and E/e'compared to the control group(P<0.05).During the research process,neither group of patients experienced any adverse reactions or events.Conclusion LGQH2 Prescription can effectively enhance exercise tolerance and cardiac function of HFpEF patients,alleviate symptoms,improve quality of life,and inhibit diastolic dysfunction of the heart,without notable adverse reactions.
